文献速递心力衰竭与心肌病

循环细胞外囊泡在慢性肾病患者心力衰竭发病中的作用

Circulating Extracellular Vesicles in the Pathogenesis of Heart Failure in Patients With Chronic Kidney Disease.
PubMed 文献 · Circulation · 2025-11-03

这项横断面研究探讨慢性肾病(CKD)患者循环细胞外囊泡(EVs)如何介导肾-心病理通讯并导致心毒性。CKD患者血浆EVs在体外和体内诱导凋亡、损害成年大鼠原代心肌细胞收缩力;CKD小鼠血浆和肾脏EVs同样具心毒性,药物清除循环EVs可显著恢复心脏功能并改善心力衰竭。CKD-EVs富集特定miRNA,其模拟物对人诱导多能干细胞来源心肌细胞具心毒性,且这些miRNA起源于CKD肾脏组织。

要点

  • CKD患者血浆EVs具心毒性,可诱导凋亡并损害心肌细胞收缩力。
  • 药物清除CKD小鼠循环EVs可显著恢复心脏功能并改善心力衰竭。
  • CKD-EV-miRNAs起源于肾脏,其水平与已确立的心脏损伤标志物相关。

核心结论

  • CKD患者循环EVs携带肾脏来源的特定miRNA,介导肾-心分子通讯,参与CKD心力衰竭发病。
  • CKD-EVs有潜力作为早期疾病检测的诊断和预后生物标志物及新治疗干预靶点。

研究设计与样本

  • 横断面研究,纳入CKD患者和腺嘌呤饮食诱导的CKD小鼠,研究EVs对心肌细胞和心脏收缩力的功能影响。
  • 通过小RNA测序和定量逆转录聚合酶链反应鉴定EVs的miRNA货物,并用miRNA模拟物测试心毒性。
  • 通过小鼠对应初级miRNA表达确定CKD-EV-miRNAs的组织和细胞来源。

主要发现

  • CKD患者血浆EVs(而非健康对照)具心毒性,在体外和体内显著诱导凋亡,并损害成年大鼠原代心肌细胞体外收缩力。
  • CKD小鼠血浆和肾脏EVs均具心毒性;药物清除循环EVs可显著恢复心脏功能并改善心力衰竭。
  • 人和小鼠CKD-EVs较对照EVs富集不同miRNAs;CKD-EV-miRNA模拟物具心毒性,损害人诱导多能干细胞来源心肌细胞收缩力并下调收缩基因表达。
  • 对应循环CKD-EV-miRNAs的内源性初级miRNAs在CKD肾脏组织(特别是CD45-veCD31-ve肾细胞)显著升高,但在CKD心脏、肝脏或外周血单核细胞中未升高,表明CKD-EV-miRNAs起源于肾脏。
  • CKD-EV-miRNA水平与已确立的心脏损伤标志物相关,揭示亚临床心脏病存在并展示肾-心病异质性。

关键数值与推荐

  • CKD患者血浆EVs在体外和体内显著诱导凋亡,并损害成年大鼠原代心肌细胞体外收缩力。
  • 药物清除CKD小鼠循环EVs可显著恢复心脏功能并改善心力衰竭。
  • CKD-EV-miRNA模拟物损害人诱导多能干细胞来源心肌细胞收缩力并下调收缩基因表达。
  • 对应循环CKD-EV-miRNAs的内源性初级miRNAs在CKD肾脏组织(CD45-veCD31-ve肾细胞)显著升高,而在CKD心脏、肝脏或外周血单核细胞中未升高。
  • CKD-EV-miRNA水平与已确立的心脏损伤标志物相关。

临床怎么用

  • CKD-EVs及其miRNA货物有望作为早期检测亚临床心脏病的诊断和预后生物标志物。
  • 靶向CKD-EVs或其miRNA可能成为慢性肾-心疾病的新治疗干预策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiovascular disease causes >50% of deaths in patients with advanced chronic kidney disease (CKD). Clinical studies suggest that kidney-derived factors contribute to cardiovascular disease development in CKD, independently of comorbidities. However, to date, no kidney-specific humoral risk factor that triggers direct cardiotoxicity has been identified. In this cross-sectional study, we investigate how, in patients with CKD, circulating extracellular vesicles (EVs) facilitate pathological kidney-heart communication, thereby causing cardiotoxicity, impairing cardiac function, and contributing to heart failure progression. METHODS: We investigated the function of EVs from patients with CKD and adenine diet-induced CKD mice on cardiomyocyte and cardiac contractility. microRNA (miRNA) cargo of EVs was identified by small RNA sequencing and quantitative reverse transcription polymerase chain reaction, and their cardiotoxicity was tested by using miRNA mimics. Tissue and cellular origin of CKD-EV-miRNAs were determined from their corresponding primary miRNA expressions in mice. RESULTS: EVs from plasma of patients with CKD, but not from healthy controls, were cardiotoxic; they significantly induced apoptosis both in vitro and in vivo and impaired contractility of adult rat primary cardiomyocytes in vitro. Likewise, EVs from both plasma and kidneys of CKD mice were cardiotoxic. Pharmacologically depleting circulating EVs in CKD mice significantly recovered cardiac function and ameliorated heart failure, improvements that suggest CKD-EVs play a causal role in heart failure pathogenesis. Both human and mouse CKD-EVs were enriched in distinct miRNAs compared with control EVs. CKD-EV-miRNA mimics were cardiotoxic, impairing contractility and downregulating contractile gene expression in human induced pluripotent stem cell-derived cardiomyocytes. It is interesting that levels of endogenous primary miRNAs corresponding to circulating CKD-EV-miRNAs were significantly higher in CKD kidney tissues, specifically in CD45-veCD31-ve renal cells, but not in CKD hearts, CKD livers, or CKD-peripheral blood mononuclear cells, a result that indicates CKD-EV-miRNAs originate renally. It is remarkable that CKD-EV-miRNA levels correlated with established markers of cardiac injury, thus uncovering the presence of subclinical heart disease and demonstrating heterogeneity in reno-cardiac disease. CONCLUSIONS: Collectively, our human subject and mouse studies show that circulating CKD-EVs, carrying distinct renal-derived miRNAs, mediate the molecular crosstalk that contributes to the pathogenesis of heart failure in CKD. Consequently, CKD-EVs hold promise as diagnostic and prognostic biomarkers for early disease detection and as targets for novel therapeutic interventions in chronic reno-cardiac disease.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Li, Raisinghani, Gallinat, et al. Circulating Extracellular Vesicles in the Pathogenesis of Heart Failure in Patients With Chronic Kidney Disease. Circulation. 2025. PMID: 41178538. doi:10.1161/CIRCULATIONAHA.125.075579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。